Woodcock: black boxes shouldn't be the 'new warnings section'

Share this article:
Responding to criticism of why it took 15 years to order a black box for fluoroquinolones, the FDA's Janet Woodcock said: “If we put every serious drug ADR in a black box, black boxes will just become the new warnings section, since most drugs have some serious ADRs associated with them.” 
Share this article:

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.